Professor of Medicine, University Paris Descartes-HEGP. Oncology department.
Director of the Inserm unit U1162: “Functional genomic of solid tumors”, Paris France
Chairman of the scientific committee CSS2 at Inserm “Genetic, Epigenetic and Cancer”
1990 Doctor in Medicine, University Paris 7, France
1994 Specialization in Internal Medicine (AIHP)
1994 PhD in life science, Fundamental Basis of Oncogenesis, University Paris 7
1998 Agreement for Research Direction (HDR), University Paris 7
1987-1994 Resident in Internal Medicine, Hopitaux de Paris, in alternation with PhD.
1994‑1996 Post-doctoral research Fellow in Genetic-Oncology, Institut Curie (Director: Gilles Thomas)
2008-present Director of the Inserm U1162 (ex U674) laboratory « Functional genomic of solid tumors »
1996‑2007 Staff Inserm scientist at unit U434 then U674, group Leader
Editorial and Review Activities
Member of scientific committees
Institut National du Cancer (Inca) chairman of the « Translational Research proposal 2009 », chairman of the IGR Foundation scientific committee. Member of several scientific boards: Ligue National de recherche sur le Cancer (LNCC), Association pour la recherche sur le Cancer (ARC, CN2), Agence Nationale pour la recherche sur le Sida et les hépatite virales (ANRS, CSS4), Institut Universitaire d’Hématologie (IUH), Inserm scientific committees (CT1, 2003-2007; AVENIR 2007-2010).
Member of the governing board of ILCA (International Liver Cancer Association); co-organizer of the liver FASEB meeting (2012), Liver tumor AACR symposium (2013), EASL HCC conference (2014)
Hepatocellular carcinoma (HCC) is one of the leading causes of death by cancer worldwide. It is mainly developed on cirrhosis due to chronic hepatitis B and C, metabolic and alcoholic liver diseases in western countries. In contrast, hepatocellular adenomas are rare benign liver tumors frequently developed in women after oral contraception. Recent advances in molecular classification and dissection of genetic and epigenetic drivers have increased our knowledge of the molecular diversity of benign and malignant liver tumors. Using genomic approaches, we identified several new oncogenes and tumor suppressor genes and we described a molecular classification of hepatocellular adenomas that is used in clinical routine. Recently, using sequencing, we identified TERT promoter mutations activating telomerase as the most important mechanism of malignant transformation of both adenoma in carcinoma and of cirrhotic nodules in carcinoma. We also found new etiological factors predisposing to liver tumor development and new drug targets.